BD creates a sustainable medical technology institute to reduce the environmental impact of its product portfolio

0

The Institute will drive sustainable innovation in three areas of environmental stewardship, driving progress towards the company’s environmental, social and governance (ESG) commitments for 2030+

FRANKLIN LAKES, NJ, April 22, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world’s leading medical technology companies, today announced the creation of the Institute of Sustainable Medical Technologya practice model within the organization that will bring together BD researchers and engineers, as well as quality, regulatory, policy and operational expertise, to focus on impact reduction environment of the company’s product portfolio in three areas, including adopting sustainable product design strategies, developing and deploying sustainable sterilization technologies, and addressing materials of concern (MOC).

The Institute will serve as an example of how the company continues to advance the world of healthcare by prioritizing safe, high-quality products for patients, while pursuing its environmental, social and governance strategy. (ESG).

“As part of our ESG strategy, we have made commitments in specific areas where we see the most opportunity for BD to create meaningful and measurable change over the next decade,” said Maureen Mazurek, vice president, sustainability and environmental health and safety (EHS) at BD. “In order to achieve these commitments, we have established a set of goals to track and measure our success, and this includes how to reduce the environmental impact of our product portfolio and meet the sustainability needs of our customers. These priorities led us to form the Sustainable Institute of Medical Technology.”

dr. Amit Limayedirector of the Sustainable Medical Technology Institute and director of sustainability research and development at BD, added, “By enabling our teams to harness deep expertise in areas such as engineering and materials science, coupled With access to cutting-edge research, technology, and government and academic partnerships, we are well positioned to be the best environmental stewards of our portfolio. Our vision is to create a strategic roadmap that will become an integral part of the organization, demonstrating how an ethical and sustainable business can drive growth, while meeting patient expectations and customer needs in the most environmentally responsible way. possible environment.”

The Institute will operate in North America, Europe and Asia, and will collaborate with cross-functional teams within the company’s business units, including research and development, regulatory, quality, policy and operations roles, with the aim of ensuring accountability and a streamlined sustainability efforts, as well as further addressing sustainability needs within industry and global regulators. Key initial efforts include re-establishing a set of minimum environmental and human health criteria for new products and product changes aligned with the company’s ESG 2030+ commitments and targets, and identifying new ways to reduce, reuse, recycle or replace materials. These efforts will inform the company’s product lifecycle roadmap and enable the adoption of a sustainable product development process by design.

Visit the company’s website to learn more about its environmental, social and governance strategy and commitment to advancing business, planet, community and human health; and for more information on innovation at BD, visit https://www.bd.com/en-us/about-bd/innovation-at-bd.

About comics

BD is one of the world’s largest global medical technology companies and advances the world of healthcare by improving medical discovery, diagnostics and care delivery. The company supports heroes on the front lines of healthcare by developing innovative technologies, services and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help improve the safety and efficiency of the clinician care delivery process, enable laboratory scientists to accurately detect disease, and advance capabilities of researchers to develop the next generation of diagnostics and therapies. BD is present in virtually every country and partners with organizations around the world to solve some of the world’s toughest health issues. By working closely with its customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information about BD, visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

contacts:




Media:

Investors:



Jessica Offerjost

Francesca DeMartino

Public Relations Comics

SVP, Head of Investor Relations

201.258.0964

201.847.5743

[email protected]

[email protected]

COMIC SOURCE (Becton, Dickinson and Company)



Source link

Share.

Comments are closed.